Our current products include the MFCS series of microfluidic flow control systems, based on the proprietary FASTAB™ technology. Fundamental studies in micro or nano hydrodynamics, nanoliter dispensing, fast mixing, bioassays, hybridization arrays, lab-on-chip electrophoresis, micro-TAS, perfusion and accurate control of cells environment, flow cytometry, combinatorial chemistry, diagnosis, are a few examples of applications in which MFCS can make your life much easier, and open unbounded routes to your imagination.

Fluigent will also introduce soon on the market innovative matrices for capillary electrophoretic detection of unknown mutations. Based on the proprietary EMMA™ technology, validated at Curie Institute's hospital for the detection of mutations. These matrices are compatible with most existing capillary DNA sequencers, and allow unprecedented sensitivity, throughput and cost effectiveness.

Fluigent, a spinoff of Curie Institute and CNRS, owns or licences a portfolio of issued or pending patents belonging to 7 families, and covering its core technologies in flow control, microfluidic devices, polymers, colloids and analytical methods. Our customers include academic and industrial research laboratories in physics, chemistry, biology, and clinical diagnostic centers. The company's products are sold directly from our Paris headquarters, and will be soon available through distributors worldwide. We also propose OEM products and customized development of building blocks or complete solutions based on our proprietary technologies, for the pharmaceutical and diagnosis industry.